0001161697-21-000129.txt : 20210225 0001161697-21-000129.hdr.sgml : 20210225 20210225173050 ACCESSION NUMBER: 0001161697-21-000129 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20210204 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210225 DATE AS OF CHANGE: 20210225 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AngioSoma, Inc. CENTRAL INDEX KEY: 0001502152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273480481 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-55072 FILM NUMBER: 21682008 BUSINESS ADDRESS: STREET 1: 2500 WILCREST DRIVE, 3RD FLOOR CITY: HOUSTON STATE: TX ZIP: 77042 BUSINESS PHONE: 832-781-8521 MAIL ADDRESS: STREET 1: 2500 WILCREST DRIVE, 3RD FLOOR CITY: HOUSTON STATE: TX ZIP: 77042 FORMER COMPANY: FORMER CONFORMED NAME: First Titan Corp. DATE OF NAME CHANGE: 20100927 8-K 1 form_8-k.htm FORM 8-K CURRENT REPORT FOR 02-04-2021


 


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K


CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934


Date of Report (Date of earliest event reported) February 4, 2021



AngioSoma, Inc.

(Exact name of registrant as specified in its charter)

 

Wyoming

333-170315

27-3480481

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)


2500 Wilcrest Drive, 3rd Floor

Houston, Texas 77042

(Address of principal executive offices)


832-781-8521
www.AngioSoma.com

(Registrant’s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common

SOAN

N/A


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ☒              


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


 



Item 7.01 Regulation FD Disclosure.


AngioSoma, Inc. (the “Company”)’s subsidiary, SomaCeuticals, Inc., has defined its mission to bring its enhanced treatment for Multiple Sclerosis to patients worldwide.


As of February 4, 2021, the Company amended and restated its Exclusive Global Multiple Sclerosis License Agreement to give both parties a stronger and more robust platform to move synergistically forward to market and license U.S. patent 10,610,592 issued to Fabrizio de Silvestri, Terni, Italy, as inventor, April 7, 2020.


Multiple Sclerosis (MS) is a chronic disease in which the immune system of the individual attacks the central nervous system and affects the nerve cells. The disease can manifest with a wide range of neurological symptoms and can progress to total physical and cognitive disability. There are many different symptoms of MS, including fatigue, numbness, walking and balance problems, bladder dysfunction, bowel dysfunction, vision problems, dizziness and vertigo, sexual dysfunction, pain, cognitive dysfunction, emotional changes, depression and spasticity.


There is no known cure using current treatments and is the most common immune-mediated disorder affecting the central nervous system. With over 2.3 million people affected and with each individual spending approximately $70,000 per year, MS ranked eighth by drug invoice spending among the top therapeutic classes in the U.S. in 2016, representing nearly $19 billion in drug spending alone.


Item 9.01 Financial Statements and Exhibits.


Exhibits


99.1 Press Release dated February 11, 2021



SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 

AngioSoma, Inc.

 

 

Dated: February 25, 2021

By:  /s/ Alex K. Blankenship

 

Name:  Alex K. Blankenship

Title:  President and CEO


- 2 -


EX-99 2 ex_99-1.htm PRESS RELEASE DATED FEBRUARY 11, 2021

Exhibit 99.1


 

Angiosoma and its Subsidiary Somaceuticals Announce Amended and Restated Execution of Global License for Multiple Sclerosis Patent

 

Houston, February 11, 2021 -- AngioSoma Inc. (OTC: SOAN) (“AngioSoma” or the “Company”), through its wholly-owned subsidiary, SomaCeuticals, Inc., is pleased to announce that the Exclusive Global Multiple Sclerosis License Agreement dated August 23, 2020 has been amended and restated as of February 4, 2021 to give both parties a stronger and more robust platform to move synergistically forward to market and license Patent 10,619,592 issued to Fabrizio de Silvestri as inventor.

 

Fabrizio de Silvestri stated, “It is wonderful that Jim Katzaroff and his group are actively interviewing Contract Research Organizations as well as possible funding sources. This looks to be a very exciting and critical year for AngioSoma.”

 

“I am so delighted that Jim was able to complete this transaction in a favorable manner to both parties. Now Jim will work with alacrity towards trials, and if we receive favorable results, navigate towards commercialization,” stated Alexanderia Blankenship, CEO and President of the Company.

 

About AngioSoma, Inc.

 

AngioSoma is a wellness company dedicated to bringing innovative, effective and high-quality supplement products and medical devices to the medical, wellness and adult-use markets through our marketing subsidiary, SomaCeuticalsTM. Learn more at www.muscles4U.com and htttps://muscles4u.blogstop.com. Stay up to date at Twitter: @tweetmuscles4u, Instagram and Facebook.

 

Notice Regarding Forward Looking Statements

 

This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

 

CONTACT

AngioSoma, Inc.

James C. Katzaroff

President, SomaCeuticals, Inc.

(832) 781-8521

 


GRAPHIC 3 angiosoma_logo.jpg GRAPHIC begin 644 angiosoma_logo.jpg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end